Looking to sell BigHat Biosciences stock or options?
Developer of an antibodies experimental platform designed to empower biological antibodies and other therapeutic proteins. The company's platform is agile, multi-objective, and data-driven and integrates a wet laboratory with artificial intelligence and machine learning techniques to design antibodies, enabling drug developers to create antibodies and undertake novel biotherapeutic designs.

Quadrille Capital, Quain Investments, S32, National Institute of Standards and Technology, Jonathan Golden, AME Cloud Ventures, GRIDS Capital, 8VC, Amar Hussain, MSD Global Health Innovation Fund.